181 related articles for article (PubMed ID: 33118597)
21. Basal-subtype bladder tumours show a 'hot' immunophenotype.
Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Luminal and Basal Phenotypes in Bladder Cancer.
Guo CC; Bondaruk J; Yao H; Wang Z; Zhang L; Lee S; Lee JG; Cogdell D; Zhang M; Yang G; Dadhania V; Choi W; Wei P; Gao J; Theodorescu D; Logothetis C; Dinney C; Kimmel M; Weinstein JN; McConkey DJ; Czerniak B
Sci Rep; 2020 Jun; 10(1):9743. PubMed ID: 32546765
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
25. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
[TBL] [Abstract][Full Text] [Related]
26. Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20.
Al-Sharaky DR; Abdelwahed M; Asaad N; Foda A; Abdou AG
J Immunoassay Immunochem; 2021 May; 42(3):236-251. PubMed ID: 33213275
[TBL] [Abstract][Full Text] [Related]
27. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
28. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
[TBL] [Abstract][Full Text] [Related]
29. Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology.
de Jong JJ; Narayan VM; Cronican AA; Gupta S; van Leenders GJLH; Boormans JL; Gibb EA; Konety BR
Am J Clin Pathol; 2021 Oct; 156(5):895-905. PubMed ID: 34157072
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
Queipo FJ; Unamunzaga GM; Negro BF; Fuertes SG; Cortés MÁ; Tejedor EC; Mañas CMB; Ariño AB; Sjödahl G; Beorlegui C
Virchows Arch; 2022 Aug; 481(2):191-200. PubMed ID: 35731280
[TBL] [Abstract][Full Text] [Related]
31. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
[TBL] [Abstract][Full Text] [Related]
32. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
[TBL] [Abstract][Full Text] [Related]
33. Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal-like urothelial cells: an immunohistochemical and histopathogenetic study.
Mai KT; Hakim SW; Ball CG; Flood TA; Belanger EC
Pathol Int; 2014 Aug; 64(8):375-81. PubMed ID: 25143125
[TBL] [Abstract][Full Text] [Related]
34. Morphology, immunohistochemistry characteristics, and clinical presentation of microcystic urothelial carcinoma: a series of 10 cases.
Su W; Sui W; Cheng X; Zong Y; Qin Y; Cui F
Diagn Pathol; 2023 Aug; 18(1):94. PubMed ID: 37598154
[TBL] [Abstract][Full Text] [Related]
35. Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma.
Pryma C; Villamil C; Gibb EA; Oo HZ; Seiler R; Contreras-Sanz A; Douglas J; Black PC; Wang G
Virchows Arch; 2022 Sep; 481(3):397-403. PubMed ID: 35612672
[TBL] [Abstract][Full Text] [Related]
36. Cytologic features of the nested variant of urothelial carcinoma: a study of seven cases.
Cardillo M; Reuter VE; Lin O
Cancer; 2003 Feb; 99(1):23-7. PubMed ID: 12589642
[TBL] [Abstract][Full Text] [Related]
37. Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma.
Volmar KE; Chan TY; De Marzo AM; Epstein JI
Am J Surg Pathol; 2003 Sep; 27(9):1243-52. PubMed ID: 12960809
[TBL] [Abstract][Full Text] [Related]
38. Molecular and immunohistochemical evaluation of BAP-1 antibody in bladder cancer and comparison with luminal-basal subtyping.
Gürbüz BÇ; Topal CS; Sobay R; Alkurt G; Zemheri IE
Pathol Res Pract; 2021 Jan; 217():153308. PubMed ID: 33341088
[TBL] [Abstract][Full Text] [Related]
39. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of basal cytokeratin expression in breast cancer.
Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
